



**United States Copyright Office**

Library of Congress · 101 Independence Avenue SE · Washington, DC 20559-6000 · [www.copyright.gov](http://www.copyright.gov)

March 16, 2017

Richard A. Herman, Esq.  
30850 Telegraph, Suite 250  
Bingham Farms, MI 48025

**Re: Second Request for Reconsideration for Refusal to Register 2015 EHIM  
Essentials List; Correspondence ID: 1-1GLHJER; SR # 1-2061432731**

Dear Mr. Herman:

The Review Board of the United States Copyright Office (“Board”) has considered EHIM’s second request for reconsideration of the Registration Program’s refusal to register a text claim in the work titled “2015 EHIM Essentials List” (“Work”). After reviewing the application, deposit copy, and relevant correspondence, along with the arguments in the second request for reconsideration, the Board affirms the Registration Program’s denial of registration.

**I. DESCRIPTION OF THE WORK**

The Work is 636 pages of text consisting of several introductory paragraphs followed by schedules of pharmaceutical products organized in alphabetical order by state. The introductory paragraphs are identical to those included in the work titled “EHIM ESSENTIALS LIST (STATE OF MICHIGAN),” registered on December 18, 2014 under the registration number TXu 1-934-686. Within each state schedule, the pharmaceutical products are listed first alphabetically according to type. For example, under the schedule for the State of Alabama, the first category is “Analgesics – Nonsteroidal Anti-Inflammatory Drugs.” Nineteen specific pharmaceutical products are listed under this category, not in alphabetical order, but according to some other methodology.

An excerpt of the Work is included in Appendix A.

**II. ADMINISTRATIVE RECORD**

On January 15, 2015, EHIM filed an application to register a copyright claim in the Work. In a July 27, 2015 letter, a Copyright Office registration specialist refused to register the claim, finding that “the material deposited represents less than the required minimum amount of original authorship on which to base a claim.” Letter from Duke Latkovic, Senior Registration Specialist, to Richard Herman (July 27, 2015).

In a letter dated October 7, 2015, EHIM requested that the Office reconsider its initial refusal to register the Work. Letter from Richard A. Herman to U.S. Copyright Office (Oct. 7, 2015) (“First Request”). After reviewing the Work in light of the points raised in the First Request, the Office re-evaluated the claims and again concluded that the Work “does not contain any new textual authorship to support a second copyright registration,” noting that “the text contained in [the Work] was the same as the text registered in *EHIM ESSENTIALS LIST (STATE OF MICHIGAN)*.” Letter from Stephanie Mason, Attorney-Advisor, to Richard Herman (Mar. 3, 2016).

In a letter dated May 31, 2016, EHIM requested that, pursuant to 37 C.F.R. § 202.5(c), the Office reconsider for a second time its refusal to register the Work. Letter from Richard A. Herman to U.S. Copyright Office (May 31, 2016) (“Second Request”). In that letter, EHIM admitted that “the introductory text is, in fact, the same.” *Id.* at 1. However, EHIM argued that “a minimum amount of originality and creativity exists, apart from the introductory text, to support registration,” and that “[w]hile certain information and facts may not be copyrightable, compilations containing such information/facts may still contain that amount of originality necessary for registration.” *Id.* at 2.

### III. DISCUSSION

#### A. *The Legal Framework: Originality*

A work may be registered if it qualifies as an “original work[] of authorship fixed in any tangible medium of expression.” 17 U.S.C. § 102(a). In this context, the term “original” consists of two components: independent creation and sufficient creativity. *See Feist Publ'ns, Inc. v. Rural Tel. Serv. Co.*, 499 U.S. 340, 345 (1991). First, the work must have been independently created by the author, *i.e.*, not copied from another work. *Id.* Second, the work must possess sufficient creativity. *Id.* Only a modicum of creativity is necessary, but the Supreme Court has ruled that some works (such as the alphabetized telephone directory at issue in *Feist*) fail to meet even this low threshold. *Id.* The Court observed that “[a]s a constitutional matter, copyright protects only those constituent elements of a work that possess more than a *de minimis* quantum of creativity.” *Id.* at 363. It further found that there can be no copyright in a work in which “the creative spark is utterly lacking or so trivial as to be virtually nonexistent.” *Id.* at 359.

The Office’s regulations implement the longstanding requirement of originality set forth in the Copyright Act and described in the *Feist* decision. *See, e.g.*, 37 C.F.R. § 202.1(a) (prohibiting registration of “[w]ords and short phrases such as names, titles, slogans; familiar symbols or designs; [and] mere variations of typographic ornamentation, lettering, or coloring”); *id.* § 202.10(a) (stating “to be acceptable as a pictorial, graphic, or sculptural work, the work must embody some creative authorship in its delineation or form”). Some combinations of common or standard design elements may contain sufficient creativity with respect to how they are juxtaposed or arranged to support a copyright. Nevertheless, not every combination or arrangement will be sufficient to meet this test. *See Feist*, 499 U.S. at 358 (finding the Copyright Act “implies that some ‘ways’ [of selecting, coordinating, or

arranging uncopyrightable material] will trigger copyright, but that others will not”). A determination of copyrightability in the combination of standard design elements depends on whether the selection, coordination, or arrangement is done in such a way as to result in copyrightable authorship. *Id.*; see also *Atari Games Corp. v. Oman*, 888 F.2d 878 (D.C. Cir. 1989).

A mere simplistic arrangement of non-protectable elements does not demonstrate the level of creativity necessary to warrant protection. For example, the United States District Court for the Southern District of New York upheld the Copyright Office’s refusal to register simple designs consisting of two linked letter “C” shapes “facing each other in a mirrored relationship” and two unlinked letter “C” shapes “in a mirrored relationship and positioned perpendicular to the linked elements.” *Coach, Inc. v. Peters*, 386 F. Supp. 2d 495, 496 (S.D.N.Y. 2005). Likewise, the Ninth Circuit has held that a glass sculpture of a jellyfish consisting of clear glass, an oblong shroud, bright colors, vertical orientation, and the stereotypical jellyfish form did not merit copyright protection. See *Satava v. Lowry*, 323 F.3d 805, 811 (9th Cir. 2003). The language in *Satava* is particularly instructive:

It is true, of course, that a *combination* of unprotectable elements may qualify for copyright protection. But it is not true that *any* combination of unprotectable elements automatically qualifies for copyright protection. Our case law suggests, and we hold today, that a combination of unprotectable elements is eligible for copyright protection only if those elements are numerous enough and their selection and arrangement original enough that their combination constitutes an original work of authorship.

*Id.* (internal citations omitted).

### **B. Analysis of the Work**

After carefully examining the Work and applying the legal standards discussed above, the Board finds that the Work does not contain the requisite separable authorship necessary to sustain a claim to copyright.

EHIM has already acknowledged that the introductory text on the first page of the Work is identical to that prefacing the work “EHIM ESSENTIALS LIST (STATE OF MICHIGAN),” registered on December 18, 2014 under registration number TXu 1-934-686. Therefore, the Board considers only the lists of pharmaceutical products on pages 2 through 636.

EHIM does not seek to register a copyright claim in the name of each pharmaceutical product, of course, but solely in the selection and arrangement of these product names. See Second Request at 2. It argues that the compilations of pharmaceutical product names are “original works of authorship, maintaining the requisite amount of creativity in and of themselves.” *Id.* It is undisputed that uncopyrightable elements may be protectable if selected and combined “in a distinctive manner indicating some ingenuity.” *Atari Games Corp.*, 888 F.2d at 883. And EHIM correctly notes that “compilations containing . . .

information/facts may still contain that amount of originality necessary for registration.” Second Request at 2.


However, here the Board finds that the selection, coordination, and arrangement of the Work’s basic elements—categories of medications and names of medications—is insufficient to render the Work original. These are concededly unprotectable facts, and, as the Ninth Circuit stated in *Satava*, “a combination of unprotectable elements is eligible for copyright protection only if those elements are numerous enough and their selection and arrangement original enough that their combination constitutes an original work of authorship.” 323 F.3d 805 at 811. Here, the alphabetical listing of states, within which are alphabetical listings of medication categories, with sub-categories also listed alphabetically, are arranged in as commonplace a manner as possible. EHIM states that “the compilation and selection of the medications were chosen by EHIM to be included, [and] the order in which they are placed was created by EHIM.” Second Request at 2. However, EHIM does not demonstrate what it is about the compilation, selection, and order of placement of the medications that constitutes creative authorship. There is no indication that EHIM selected, based on any independent criteria, only certain medications to place in each sub-category, nor that the categories and sub-categories themselves are anything more than descriptive facts. While it is true that the medications are not listed within each sub-category in alphabetical order, EHIM presents no evidence that the order of listing embodies any creativity or is based on any organizing principle. Instead, the entire Work is merely a statement of the following fact, without more: EHIM’s pharmacy benefits cover the drugs listed in the Work. *See* COMPENDIUM (THIRD) § 707 (listing facts as an example of a work that does not satisfy the requirements of section 102(a) of the Copyright Act).

Accordingly, the Board finds that the Work’s selection, coordination, and arrangement of unprotectable facts and information do not demonstrate the creative authorship necessary for copyright registration.

#### IV. CONCLUSION

For the reasons stated herein, the Review Board of the United States Copyright Office affirms the refusal to register the copyright claim in the Work. Pursuant to 37 C.F.R. § 202.5(g), this decision constitutes final agency action in this matter.

BY:



Chris Weston

Copyright Office Review Board

## APPENDIX:

Excerpt (pages 1-10) of "2015 EHIM Essentials List"

## 2015 EHIM *Essentials List*

*A pharmacy plan that utilizes an Out-of-Pocket (OOP) maximum shall be calculated based on therapy classes that are considered Essential Health Benefits (EHBs) under healthcare law.*

*Only out-of-pocket expenses for prescriptions that are included on this Essentials List **AND** covered within a group's plan design will accumulate towards the 2015 OOP Maximum. Medications that are not included in this list may be covered by the prescription program however the out-of-pocket costs will not accumulate toward your out-of-pocket maximum.*

*Please refer to the Prescription Benefit Handbook for a detailed description of your actual plan design & copay levels.*

*Some of the medications included in this list will be subject to your specific plan design and formulary requirements. Clinical management, such as Step Therapy, Prior Authorization, and/or Quantity Limits and may be utilized before a drug can be covered by your prescription program.*

*This list applies to FDA-approved generic drugs, even if those drugs are not specifically listed as generic at the time of distribution.*

*This list is subject to change at any time without notice.*

## ALABAMA

### ANALGESICS - NONSTEROIDAL ANTI-INFLAMMATORY DRUGS

IBUPROFEN	NAPROXEN	MELOXICAM	DICLOFENAC POTASSIUM
DICLOFENAC SODIUM	ETODOLAC	INDOMETHACIN	KETOROLAC
NABUMETONE	OXAPROZIN	PIROXICAM	SALSALATE
SULINDAC	DIFLUNISAL	FENOPROFEN	FLURBIPROFEN
KETOPROFEN	MEFENAMIC ACID	TOLMETIN	

### ANALGESICS - OPIOID ANALGESICS, LONG-ACTING

MORPHINE SULFATE SR

### ANALGESICS - OPIOID ANALGESICS, SHORT-ACTING

TRAMADOL

### ANESTHETICS - LOCAL ANESTHETICS

LIDOCAINE CREAM      LIDOCAINE/PRILOCAINE      LIDOCAINE PATCH

### ANTI-ADDICTION/SUBSTANCE ABUSE TREATMENT AGENTS - ALCOHOL DETERRENTS/ANTI-CRAVING

DISULFIRAM      CHANTIX      CAMPRAL

### ANTI-ADDICTION/SUBSTANCE ABUSE TREATMENT AGENTS - OPIOID ANTAGONISTS

BUPRENORPHINE      NALOXONE

### ANTI-ADDICTION/SUBSTANCE ABUSE TREATMENT AGENTS - SMOKING CESSATION AGENTS

BUPROPION      NICOTROL PATCH      CHANTIX

### ANTIBACTERIALS - AMINOGLYCOSIDES

GENTAMICIN	TOBRAMYCIN	NEOMYCIN	AK-TOB
AMIKACIN	KANAMYCIN	PAROMOMYCIN	STREPTOMYCIN
TOBI			

### ANTIBACTERIALS - ANTIBACTERIALS, OTHER

TRIMETHOPRIM	NITROFURANTOIN	NITROFURANTOIN MACROCRYSTALS	METRONIDAZOLE
CLINDAMYCIN HCL	CLINDAMYCIN PHOSPHATE	MUPIROCIIN	NEO/POLY/BAC/HC
NEO/POLY/GRAMCIDIN	TRIMETHOPRIM/POLYMYXIN B	THERMAZENE	BACITRACIN
VANDAOLE	METHENAMINE	ZIANA (VELTIN)	VANCOMYCIN

### ANTIBACTERIALS - BETA-LACTAM, CEPHALOSPORINS

CEPHALEXIN	CEFUROXIME	CEFADROXIL	CEFDINIR
CEFPROZIL	CEFPODOXIME	CEFACTOR	CEFDITOREN PIVOXIL
CEDAX	SUPRAX	CEFAZOLIN	CEFTRIAXONE
CEFOTETAN	CEFOXITIN	CEFEPIME	CEFTAZIDIME

### ANTIBACTERIALS - BETA-LACTAM, OTHER

MEROPENEM      INVANZ      AZACTAM

### ANTIBACTERIALS - BETA-LACTAM, PENICILLINS

PENICILLIN V	AMOXICILLIN	AMOXICILLIN CLAVULANATE	AMPICILLIN
DICLOXACILLIN	PENICILLIN G	NAFCILLIN	AMPICILLIN/SULBACTAM
OXACILLIN	PIPERACILLIN		

### ANTIBACTERIALS - MACROLIDES

AZITHROMYCIN	ERYTHROMYCIN BASE	ERYTHROMYCIN STEARATE	ERYTHROMYCIN ETHYLSUCCINATE
CLARITHROMYCIN			

This document and the data and/or information contained in this document ("Information") are owned by EHIM. It contains legally privileged, confidential and proprietary information and/or intellectual property of EHIM that is protected from disclosure through agreement(s) and/or laws that require the recipient to keep the information confidential. The information may not be reproduced, disclosed, used and/or relied upon, in whole, or in part, without the prior written consent of EHIM. This information is also intended solely for the recipient and/or others authorized by EHIM to receive it. If you are not the intended recipient, please notify EHIM and immediately delete, shred and/or otherwise destroy the information. Any unauthorized reproduction, disclosure, access, use and/or action in reliance on the information is strictly prohibited and may entitle EHIM to legal and/or equitable remedies and damages.

**ANTIBACTERIALS - QUINOLONES**

CIPROFLOXACIN	LEVOFLOXACIN	OFLOXACIN	AVELOX
VIGAMOX	ZYMAXID	FACTIVE	NOROXIN

**ANTIBACTERIALS - SULFONAMIDES**

SMO/TMP	SODIUM SULFACETAMIDE	SULFADIAZINE	TMP/POLYMYXIN
---------	----------------------	--------------	---------------

**ANTIBACTERIALS - TETRACYCLINES**

DOXYCYCLINE	MINOCYCLINE	TETRACYCLINE	DEMECLOCYCLINE
-------------	-------------	--------------	----------------

**ANTICONVULSANTS - ANTICONVULSANTS, OTHER**

LEVETIRACETAM	BANZEL
---------------	--------

**ANTICONVULSANTS - CALCIUM CHANNEL MODIFYING AGENTS**

ZONISAMIDE	ETHOSUXIMIDE	LYRICA	CELONTIN
------------	--------------	--------	----------

**ANTICONVULSANTS - GAMMA-AMINOBUTYRIC ACID (GABA) AUGMENTING AGENTS**

GABAPENTIN	DIVALPROEX	VALPROIC ACID	PRIMIDONE
TIAGIBINE			

**ANTICONVULSANTS - GLUTAMATE REDUCING AGENTS**

LAMOTRIGINE	TOPIRAMATE	FELBAMATE
-------------	------------	-----------

**ANTICONVULSANTS - SODIUM CHANNEL AGENTS**

PHENYTOIN	CARBAMAZEPINE	OXCARBAZEPINE	APTIOM
EPITOL	PEGANONE		

**ANTIDEMENTIA AGENTS - ANTIDEMENTIA AGENTS, OTHER**

ERGOLOID MESYLATES

**ANTIDEMENTIA AGENTS - CHOLINESTERASE INHIBITORS**

DONEPEZIL	GALANTAMINE	RIVASTIGMINE
-----------	-------------	--------------

**ANTIDEMENTIA AGENTS - N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ANTAGONIST**

NAMENDA

**ANTIDEPRESSANTS - ANTIDEPRESSANTS, OTHER**

TRAZODONE	BUPROPION	MIRTAZAPINE	NEFAZODONE
MAPROTILINE	VIIBRYD	APLENZIN	OLEPTRO

**ANTIDEPRESSANTS - MONOAMINE OXIDASE INHIBITORS**

PHENELZINE	TRANLYCYPROMINE	EMSAM	MARPLAN
------------	-----------------	-------	---------

**ANTIDEPRESSANTS - SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS**

FLUOXETINE	PAROXETINE	SERTRALINE	CITALOPRAM
VENLAFAXINE	ESCITALOPRAM	FLUVOXAMINE	CYMBALTA
VIIBRYD			

**ANTIDEPRESSANTS - TRICYCLICS**

AMITRIPTYLINE	IMIPRAMINE	IMIPRAMINE PAMOATE	NORTRIPTYLINE
DOXEPIN	DESIPRAMINE	CLOMIPRAMINE	PROTRIPTYLINE
AMOXAPINE			

**ANTIEMETICS - ANTIEMETICS, OTHER**

DIPHENHYDRAMINE	MECLIZINE	PROCHLORPERAZINE	PROMETHAZINE
METOCLOPRAMIDE	TRIMETHOBENZAMIDE	DEXAMETHASONE	SCOPOLAMINE
CYCLIZINE	CESAMET		

This document and the data and/or information contained in this document ("Information") are owned by EHIM. It contains legally privileged, confidential and proprietary information and/or intellectual property of EHIM that is protected from disclosure through agreement(s) and/or laws that require the recipient to keep the Information confidential. The Information may not be reproduced, disclosed, used and/or relied upon, in whole, or in part, without the prior written consent of EHIM. This Information is also intended solely for the recipient and/or others authorized by EHIM to receive it. If you are not the intended recipient, please notify EHIM and immediately delete, shred and/or otherwise destroy the Information. Any unauthorized reproduction, disclosure, access, use and/or action in reliance on the Information is strictly prohibited and may entitle EHIM to legal and/or equitable remedies and damages.



### ANTIEMETICS - EMETOGENIC THERAPY ADJUNCTS

ONDANSETRON ANZEMET	MECLIZINE EMEND	METOCLOPRAMIDE	GRANISETRON
------------------------	--------------------	----------------	-------------

### ANTIFUNGALS - ANTIFUNGALS

FLUCONAZOLE	NYSTATIN/TRIAMCINOLONE	TERBINAFINE	NYSTATIN
CLOTRIMAZOLE	MICONAZOLE	TERCONAZOLE	ECONAZOLE
SELENIUM SULFIDE	KETOCONAZOLE	GRISEOFULVIN	UNDECYLENIC ACID
CICLOPIROX	CLOTRIM/BETAMETH	FLUCYTOSINE	VORICONAZOLE
ITRACONAZOLE	NOXAFIL	CANCIDAS	AMPHOTERICIN B
JUBLIA			

### ANTIGOUT AGENTS - ANTIGOUT AGENTS

ALLOPURINOL PROBENECID/COLCHICINE	COLCRYS	PROBENECID	ULORIC
--------------------------------------	---------	------------	--------

### ANTI-INFLAMMATORY AGENTS - GLUCOCORTICOIDS

METHYLPREDNISOLONE

### ANTI-INFLAMMATORY AGENTS - NONSTEROIDAL ANTI-INFLAMMATORY DRUGS

IBUPROFEN	NAPROXEN	MELOXICAM	DICLOFENAC POTASSIUM
DICLOFENAC SODIUM	ETODOLAC	INDOMETHACIN	KETOROLAC
NABUMETONE	OXAPROZIN	PIROXICAM	SALSALATE
SULINDAC	DIFLUNISAL	FENOPROFEN	FLURBIPROFEN
KETOPROFEN	MEFENAMIC ACID	TOLMETIN	

### ANTIMIGRAINE AGENTS - ERGOT ALKALOIDS

DIHYDROERGOTAMINE	ISOMETHEPTENE/DICHLORALP HENZAONE/APAP
-------------------	---

### ANTIMIGRAINE AGENTS - PROPHYLACTIC

PROPRANOLOL	TIMOLOL	TOPIRAMATE	GUANFACINE
-------------	---------	------------	------------

### ANTIMIGRAINE AGENTS - SEROTONIN (5-HT) 1B/1D RECEPTOR AGONISTS

SUMATRIPTAN

### ANTIMYASTHENIC AGENTS - PARASYMPATHOMIMETICS

PYRIDOSTIGMINE	GUANIDINE	REGONOL
----------------	-----------	---------

### ANTIMYCOBACTERIALS - ANTIMYCOBACTERIALS, OTHER

DAPSONE	MYCOBUTIN
---------	-----------

### ANTIMYCOBACTERIALS - ANTITUBERCULARS

ISONIAZID	RIFAMPIN	ETHAMBUTOL	PYRAZINAMIDE
PRIFTIN	ISONARIF/RIFAMATE	CAPASTAT	RIFATER
SEROMYCIN	TRECTOR		

### ANTINEOPLASTICS - ALKYLATING AGENTS

CYCLOPHOSPHAMIDE	DACARBAZINE	CEENU	IFOSFAMIDE
MATULANE	LEUKERAN	ALKERAN	

### ANTINEOPLASTICS - ANTIANGIOGENIC AGENTS

REVLIMID	THALOMID
----------	----------

### ANTINEOPLASTICS - ANTIESTROGENS/MODIFIERS

TAMOXIFEN	FARESTON	EMCYT
-----------	----------	-------

This document and the data and/or information contained in this document ("Information") are owned by EHIM. It contains legally privileged, confidential and proprietary information and/or intellectual property of EHIM that is protected from disclosure through agreement(s) and/or laws that require the recipient to keep the Information confidential. The Information may not be reproduced, disclosed, used and/or relied upon, in whole, or in part, without the prior written consent of EHIM. This Information is also intended solely for the recipient and/or others authorized by EHIM to receive it. If you are not the intended recipient, please notify EHIM and immediately delete, shred and/or otherwise destroy the Information. Any unauthorized reproduction, disclosure, access, use and/or action in reliance on the Information is strictly prohibited and may entitle EHIM to legal and/or equitable remedies and damages.

**ANTINEOPLASTICS - ANTIMETABOLITES**

HYDROXYUREA                      MERCAPTOPYRIMIDINE

**ANTINEOPLASTICS - ANINEOPLASTICS, OTHER**

AMIFOSTINE                      BLEOMYCIN                      COSMEGEN                      DACTINOMYCIN  
MITOMYCIN

**ANTINEOPLASTICS - AROMATASE INHIBITORS, 3RD GENERATION**

ANASTROZOLE                      LETROZOLE                      EXEMESTANE

**ANTINEOPLASTICS - ENZYME INHIBITORS**

TARCEVA                      GLEEVEC                      IRESSA

**ANTINEOPLASTICS - MOLECULAR TARGET INHIBITORS**

TARCEVA                      AFINITOR                      GLEEVEC                      INLYTA  
IRESSA                      JAKAFI                      NEXAVAR                      SPRYCEL  
SUTENT                      TASIGNA                      TYKERB                      VOTRIENT

**ANTINEOPLASTICS - MONOCLONAL ANTIBODIES**

HUMIRA                      CIMZIA

**ANTINEOPLASTICS - RETINOIDS**

TRETINOIN                      PANRETIN                      TARGRETIN

**ANTIPARASITICS - ANTHELMINTICS**

PYRIMETHAMINE                      MEBENDAZOLE                      STROMECHOL

**ANTIPARASITICS - ANTIPROTOZOALS**

HYDROXYCHLOROQUINE                      DAPSONE                      CHLOROQUINE                      MEFLOQUINE  
PRIMAQUINE                      QUINIDINE GLUCONATE                      QUALAQUIN                      ATOVAQUONE/PROGUANIL  
COARTEM                      DARAPRIM                      FANSIDAR                      MEPRON

**ANTIPARASITICS - PEDICULICIDES/SCABICIDES**

PERMETHRIN                      LINDANE                      MALATHION                      NATROBA  
EURAX                      STROMECHOL

**ANTIPARKINSON AGENTS - ANTICHOLINERGICS**

BENZTROPINE                      RIVASTIGMINE                      GALANTAMINE

**ANTIPARKINSON AGENTS - ANTIPARKINSON AGENTS, OTHER**

COMTAN                      STALEVO                      TASMAR

**ANTIPARKINSON AGENTS - DOPAMINE AGONISTS**

ROPINIROLE                      PRAMIPEXOLE                      BROMOCRIPTINE                      APOMORPHINE

**ANTIPARKINSON AGENTS - DOPAMINE PRECURSORS/L-AMINO ACID DECARBOXYLASE INHIBITORS**

CARBIDOPA/LEVODOPA                      LODOSYN

**ANTIPARKINSON AGENTS - MONOAMINE OXIDASE B (MAO-B) INHIBITORS**

SELEGILINE                      AZILECT

**ANTIPSYCHOTICS - 1ST GENERATION/TYPICAL**

CHLORPROMAZINE                      HALOPERIDOL                      PROCHLORPERAZINE                      THIOTHIXENE  
TRIFLUOPERAZINE                      THIORIDAZINE                      FLUPHENAZINE                      PERPHENAZINE  
LOXAPINE                      ORAP

**ANTIPSYCHOTICS - 2ND GENERATION/ATYPICAL**

RISPERIDONE	QUETIAPINE	OLANZAPINE	ZIPRASIDONE
CLOZAPINE	INVEGA	ABILIFY	SAPHRIS
LATUDA			

**ANTIPSYCHOTICS - TREATMENT-RESISTANT**

ABILIFY

**ANTISPASTICITY AGENTS - ANTISPASTICITY AGENTS**

CYCLOBENZAPRINE	BACLOFEN	TIZANIDINE	DANTROLENE
-----------------	----------	------------	------------

**ANTIVIRALS - ANTI-CYTOMEGALOVIRUS (CMV) AGENTS**

GANCICLOVIR	VALCYTE
-------------	---------

**ANTIVIRALS - ANTIHEPATITIS AGENTS**

INTRON A	PEGASYS	RIBAPAK	RIBASPHERE
RIBAVIRIN	EPIVIR HBV	HEPSERA	BARACLUE
COPEGUS	TYZEKA	VICTRELIS	INCIVEK

**ANTIVIRALS - ANTIHERPETIC AGENTS**

ACYCLOVIR	VALACYCLOVIR	FAMCICLOVIR	TRIFLURIDINE
DENAVER			

**ANTIVIRALS - ANTI-HIV AGENTS, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS**

SUSTIVA	ATRIPLA	INTELENCE	VIRAMUNE
RESCRIPTOR			

**ANTIVIRALS - ANTI-HIV AGENTS, NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS**

ZIDOVUDINE	VIREAD	EPIVIR	EMTRIVA
COMBIVIR	EPZICOM	TRIZIVIR	TRUVADA
DIDANOSINE	STAVUDINE	VIDEX	

**ANTIVIRALS - ANTI-HIV AGENTS, OTHER**

ISENTRESS	SELZENTRY	FUZEON
-----------	-----------	--------

**ANTIVIRALS - ANTI-HIV AGENTS, PROTEASE INHIBITORS**

KALETRA	PREZISTA	REYATAZ	LEXIVA
APTIVUS	INVIRASE	VIRACEPT	NORVIR
CRIXIVAN			

**ANTIVIRALS - ANTI-INFLUENZA AGENTS**

AMANTADINE	TAMIFLU	RELENZA
------------	---------	---------

**ANXIOLYTICS - ANXIOLYTICS, OTHER**

BUSPIRONE	CHLORDIAZEPOXIDE	CHLORDIAZ/CLIDIN	MEPROBAMATE
-----------	------------------	------------------	-------------

**ANXIOLYTICS - SSRIS/SNRIS (SELECTIVE SEROTONIN REUPTAKE INHIBITORS/SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS)**

FLUOXETINE	PAROXETINE	SERTRALINE	VENLAFAXINE
FLUVOXAMINE			

**BIPOLAR AGENTS - BIPOLAR AGENTS, OTHER**

RISPERIDONE	QUETIAPINE	OLANZAPINE	ZIPRASIDONE
OXCARBAZEPINE	ABILIFY		

**BIPOLAR AGENTS - MOOD STABILIZERS**

LITHIUM	VALPROATE SODIUM	LAMOTRIGINE	CARBAMAZEPINE
---------	------------------	-------------	---------------

This document and the data and/or information contained in this document ("Information") are owned by EHIM. It contains legally privileged, confidential and proprietary information and/or intellectual property of EHIM that is protected from disclosure through agreement(s) and/or laws that require the recipient to keep the information confidential. The information may not be reproduced, disclosed, used and/or relied upon, in whole, or in part, without the prior written consent of EHIM. This information is also intended solely for the recipient and/or others authorized by EHIM to receive it. If you are not the intended recipient, please notify EHIM and immediately delete, shred and/or otherwise destroy the information. Any unauthorized reproduction, disclosure, access, use and/or action in reliance on the information is strictly prohibited and may entitle EHIM to legal and/or equitable remedies and damages.

**BLOOD GLUCOSE REGULATORS - ANTIDIABETIC AGENTS**

METFORMIN	GLIPIZIDE	GLIMEPIRIDE	GLYBURIDE
PIOGLITAZONE	ACARBOSE	NATEGLINIDE	GLIPIZIDE/METFORMIN
GLYBURIDE/METFORMIN	PIOGLITAZONE/METFORMIN	PIOGLITAZINE/GLIMEPIRIDE	CHLORPROPAMIDE
BROMOCRIPTINE	PRANDIMET	JANUVIA	JANUMET
JENTADUETO	AVANDIA	AVANDARYL	VICTOZA
BYETTA			

**BLOOD GLUCOSE REGULATORS - GLYCEMIC AGENTS**

GLUCAGON	PROGLYCEM
----------	-----------

**BLOOD GLUCOSE REGULATORS - INSULINS**

HUMULIN	NOVOLIN R	NOVOLIN N	NOVOLIN 70/30
NOVOLOG	HUMALOG	LEVEMIR	LANTUS
NOVOLOG MIX	APIDRA		

**BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS - ANTICOAGULANTS**

WARFARIN	HEPARIN
----------	---------

**BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS - BLOOD FORMATION MODIFIERS**

PROCRIT	EPOGEN	GRANIX	ARANESP
NEUPOGEN	NEUMEGA	LEUKINE	

**BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS - COAGULANTS**

CYKLOKAPRON
-------------

**BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS - PLATELET MODIFYING AGENTS**

CLOPIDOGREL	CILOSTAZOL	DIPYRIDAMOLE	ANAGRELIDE
AGGRENOX	EFFIENT	XARELTO	PRADAXA

**CARDIOVASCULAR AGENTS - ALPHA-ADRENERGIC AGONISTS**

CLONIDINE	METHYLDOPA	METHYLDOPA/HCTZ	MIDODRINE
-----------	------------	-----------------	-----------

**CARDIOVASCULAR AGENTS - ALPHA-ADRENERGIC BLOCKING AGENTS**

TAMSULOSIN	DOXAZOSIN	TERAZOSIN	PRAZOSIN
------------	-----------	-----------	----------

**CARDIOVASCULAR AGENTS - ANGIOTENSIN II RECEPTOR ANTAGONISTS**

LOSARTAN	LOSARTAN/HCTZ	IRBESARTAN	EPROSARTAN
DIOVAN	ATACAND	MICARDIS	BENICAR

**CARDIOVASCULAR AGENTS - ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS**

LISINAPRIL	LISINAPRIL/HCTZ	BENAZEPRIL	CAPTOPRIL
RAMIPRIL	QUINAPRIL	FOSINOPRIL	MOEXIPRIL
TRANDOLAPRIL	PERINDOPRIL		

**CARDIOVASCULAR AGENTS - ANTIARRHYTHMICS**

AMIODARONE	DISOPYRAMIDE	FLECAINIDE	PROPAFENONE
SOTALOL	MEXILETINE	QUINIDINE GLUCONATE	QUINIDINE SULFATE
TIKOSYN	SORINE		

**CARDIOVASCULAR AGENTS - BETA-ADRENERGIC BLOCKING AGENTS**

METOPROLOL TARTRATE	ATENOLOL	BISOPROLOL	PROPRANOLOL
CARVEDILOL	LABETALOL	METOPROLOL SUCCINATE	NADOLOL
BYSTOLIC	ACEBUTOLOL	BETAXOLOL	TIMOLOL
PINDOLOL			

**CARDIOVASCULAR AGENTS - CALCIUM CHANNEL BLOCKING AGENTS**

AMLODIPINE	DILTIAZEM	VERAPAMIL	NIFEDIPINE
NIFEDIPINE	FELODIPINE	NISOLDIPINE	ISRADIPINE
NIMODIPINE			

**CARDIOVASCULAR AGENTS - CARDIOVASCULAR AGENTS, OTHER**

PENTOXIFYLLINE	EPLERENONE	TEKTURNA	TEKTURNA HCT
----------------	------------	----------	--------------

**CARDIOVASCULAR AGENTS - DIURETICS, CARBONIC ANHYDRASE INHIBITORS**

ACETAZOLAMIDE	METHAZOLAMIDE
---------------	---------------

**CARDIOVASCULAR AGENTS - DIURETICS, LOOP**

FUROSEMIDE	BUMETANIDE	TORSEMIDE	EDECIN
------------	------------	-----------	--------

**CARDIOVASCULAR AGENTS - DIURETICS, POTASSIUM-SPARING**

SPIRONOLACTONE	AMILORIDE	SPIRINOLACTONE/HCTZ	TRIAMTERENE/HCTZ
----------------	-----------	---------------------	------------------

**CARDIOVASCULAR AGENTS - DIURETICS, THIAZIDE**

HCTZ	CHLORTHALIDONE	INDAPAMIDE	METOLAZONE
CHLOROTHIAZIDE	METHYCLOTHIAZIDE		

**CARDIOVASCULAR AGENTS - DYSLIPIDEMICS, FIBRIC ACID DERIVATIVES**

FENOFIBRATE	FENOFIBRIC ACID
-------------	-----------------

**CARDIOVASCULAR AGENTS - DYSLIPIDEMICS, HMG COA REDUCTASE INHIBITORS**

SIMVASTATIN	ATORVASTATIN	LOVASTATIN	PRAVASTATIN
FLUVASTATIN	CRESTOR	LIVALO	

**CARDIOVASCULAR AGENTS - DYSLIPIDEMICS, OTHER**

NIACIN	CHOLESTYRAMINE	COLESTIPOL	LOVAZA
ZETIA	VYTORIN		

**CARDIOVASCULAR AGENTS - VASODILATORS, DIRECT-ACTING ARTERIAL**

HYDRALAZINE	NITROGLYCERIN	NITROGLYCERIN
-------------	---------------	---------------

**CARDIOVASCULAR AGENTS - VASODILATORS, DIRECT-ACTING ARTERIAL/VENOUS**

ISOSORBIDE MONONITRATE	ISOSORBIDE DINITRATE	NITROPRUSSIDE
------------------------	----------------------	---------------

**CENTRAL NERVOUS SYSTEM AGENTS - ATTENTION DEFICIT HYPERACTIVITY DISORDER AGENTS, AMPHETAMINES**

AMPHETAMINE SALTS	DEXTROAMPHETAMINE	VYVANSE	METHAMPHETAMINE
-------------------	-------------------	---------	-----------------

**CENTRAL NERVOUS SYSTEM AGENTS - ATTENTION DEFICIT HYPERACTIVITY DISORDER AGENTS, NON-AMPHETAMINES**

METHYLPHENIDATE	DEXMETHYLPHENIDATE	MODAFINIL	STRATTERA
-----------------	--------------------	-----------	-----------

**CENTRAL NERVOUS SYSTEM AGENTS - CENTRAL NERVOUS SYSTEM AGENTS, OTHER**

AMITRIPTYLINE	TRAZODONE	CAFFEINE	NUEDEXTA
---------------	-----------	----------	----------

**CENTRAL NERVOUS SYSTEM AGENTS - FIBROMYALGIA AGENTS**

DULOXETINE	LYRICA	SAVELLA
------------	--------	---------

**CENTRAL NERVOUS SYSTEM AGENTS - MULTIPLE SCLEROSIS AGENTS**

COPAXONE	BETASERON	REBIF	AMPYRA
GILENYA	TECFIDERA	TYSABRI	

This document and the data and/or information contained in this document ("Information") are owned by EHIM. It contains legally privileged, confidential and proprietary information and/or intellectual property of EHIM that is protected from disclosure through agreement(s) and/or laws that require the recipient to keep the information confidential. The information may not be reproduced, disclosed, used and/or relied upon, in whole, or in part, without the prior written consent of EHIM. This information is also intended solely for the recipient and/or others authorized by EHIM to receive it. If you are not the intended recipient, please notify EHIM and immediately delete, shred and/or otherwise destroy the information. Any unauthorized reproduction, disclosure, access, use and/or action in reliance on the information is strictly prohibited and may entitle EHIM to legal and/or equitable remedies and damages.

**DENTAL AND ORAL AGENTS - DENTAL AND ORAL AGENTS**

CHLORHEXIDINE OROPHARYNGEAL CEVILIMINE	DOXYCYCLINE  KEPIVANCE	TRIAMCINOLONE PASTE  LURIDE	PILOCARPINE
--	------------------------------	-----------------------------------	-------------

**DERMATOLOGICAL AGENTS - DERMATOLOGICAL AGENTS**

AMMONIUM LACTATE ERYTHROMYCIN ERYTHROMYCIN/BPO PODOFILOX SOLUTION IMIQUIMOD PROTOPIC UVADEX FINACEA OXSORALEN	BENZOYL PEROXIDE SELENIUM SULFIDE METRONIDAZOLE ADAPALENE SOLARAZE TRETINOIN EXELDERM AVITA REGRANEX	CLINDAMYCIN TOPICAL SODIUM SULFACETAMIDE TAZORAC CALCIPOTRIENE TRETINOIN SANTYL VEREGEN CLARAVIS PLEXION	AZELEX CLINDAMYCIN/BPO ULESFIA FLUOROURACIL ELIDEL EURAX ZONALON EPIDUO
---	--	--	--

**ENZYME REPLACEMENT/MODIFIERS - ENZYME REPLACEMENT/MODIFIERS**

ZENPEP ADAGEN CEREZYME FABRAZYME	PANCREASE ALDURAZYME CYSTADANE MYOZYME	KUVAN BUPHENYL CYSTAGON NAGLAZYME	NEXAVAR CEREDASE ELAPRASE
---	---	--	---------------------------------

**GASTROINTESTINAL AGENTS - ANTISPASMODICS, GASTROINTESTINAL**

ATROPINE/DIPHENOXYLATE DONNATAL	DICYCLOMINE HYOSCYAMINE	ATROPINE	GLYCOPYRROLATE
------------------------------------	----------------------------	----------	----------------

**GASTROINTESTINAL AGENTS - GASTROINTESTINAL AGENTS, OTHER**

ATROPINE/DIPHENOXYLATE TRILYTE	LACTULOSE XENICAL	LANSOPRAZOLE	URSODIOL
-----------------------------------	----------------------	--------------	----------

**GASTROINTESTINAL AGENTS - HISTAMINE (H2) RECEPTOR ANTAGONISTS**

RANITIDINE	FAMOTIDINE	NIZATIDINE	CIMETIDINE
------------	------------	------------	------------

**GASTROINTESTINAL AGENTS - IRRITABLE BOWEL SYNDROME AGENTS**

DICYCLOMINE	PHENOBARB/HYOSC/ATROP/S COP
-------------	--------------------------------

**GASTROINTESTINAL AGENTS - LAXATIVES**

SENNOSIDES	PEG 3350	LACTULOSE
------------	----------	-----------

**GASTROINTESTINAL AGENTS - PROTECTANTS**

SUCRALFATE	MISOPROSTOL
------------	-------------

**GASTROINTESTINAL AGENTS - PROTON PUMP INHIBITORS**

OMEPRAZOLE RABEPRAZOLE	PANTOPRAZOLE ZEGERID	LANSOPRAZOLE	ESOMEPRAZOLE
---------------------------	-------------------------	--------------	--------------

**GENITOURINARY AGENTS - ANTISPASMODICS, URINARY**

OXYBUTYNIN TOVIAZ	TOLTERODINE VESICARE	TROSPIUM ENABLEX	OXYTROL
----------------------	-------------------------	---------------------	---------

**GENITOURINARY AGENTS - BENIGN PROSTATIC HYPERTROPHY AGENTS**

TAMSULOSIN PRAZOSIN JALYN	FINASTERIDE ALFUZOSIN	TERAZOSIN AVODART	DOXAZOSIN RAPAFLO
---------------------------------	--------------------------	----------------------	----------------------

**GENITOURINARY AGENTS - GENITOURINARY AGENTS, OTHER**

PHENAZOPYRIDINE	BETHANECHOL	BETHANECHOL
-----------------	-------------	-------------

This document and the data and/or information contained in this document ("Information") are owned by EHIM. It contains legally privileged, confidential and proprietary information and/or intellectual property of EHIM that is protected from disclosure through agreement(s) and/or laws that require the recipient to keep the information confidential. The information may not be reproduced, disclosed, used and/or relied upon, in whole, or in part, without the prior written consent of EHIM. This information is also intended solely for the recipient and/or others authorized by EHIM to receive it. If you are not the intended recipient, please notify EHIM and immediately delete, shred and/or otherwise destroy the information. Any unauthorized reproduction, disclosure, access, use and/or action in reliance on the information is strictly prohibited and may entitle EHIM to legal and/or equitable remedies and damages.

**GENITOURINARY AGENTS - PHOSPHATE BINDERS**

CALCIUM ACETATE                      RENVELA                      RENAGEL

**HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (ADRENAL) - GLUCOCORTICOIDS/MINERALOCORTICOIDS**

HYDROCORTISONE	BETAMETHASONE VALERATE	BETAMETH DIPROP	CLOBETASOL
DESONIDE	DESOXIMETASONE	DIFLORASONE	FLUCINOLONE
HYDROCORTISONE BUTYRATE	HYDROCORTISONE VALERATE	METHYLPREDNISOLONE	MOMETASONE
ALCLOMETASONE	AMCINONIDE	AUGMENTED BETAMETHASONE	CLOBETASOL E
DEXAMETHASONE	FLUDROCORTISONE	HALOBETASOL	PREDNICARBATE
CLOBEX	CORTISONE	SCALACORT	

**HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (PITUITARY) - HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (PITUITARY)**

DESMOPRESSIN                      CHORIONIC GONADOTROPIN                      GENOTROPIN                      SEROSTIM

**HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (PROSTAGLANDINS) - HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (PROSTAGLANDINS)**

ALPROSTADIL

**HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (SEX HORMONES/MODIFIERS) - ANABOLIC STEROIDS**

OXANDROLONE                      ANADROL

**HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (SEX HORMONES/MODIFIERS) - ANDROGENS**

FIRST-TESTOSTERONE                      TESTOSTERONE                      DANAZOL                      ANDROXY

**HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (SEX HORMONES/MODIFIERS) - ESTROGENS**

CLIMARA                      ACTIVELLA                      ALORA                      COMBIPATCH

**HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (SEX HORMONES/MODIFIERS) - PROGESTINS**

MEDROXYPROGESTERONE                      MEDROXYPRO ACETATE                      MEGESTROL                      PROGESTERONE MICRONIZED

**HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (SEX HORMONES/MODIFIERS) - SELECTIVE ESTROGEN RECEPTOR MODIFYING AGENTS**

EVISTA

**HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (THYROID) - HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (THYROID)**

LEVOTHYROXINE                      LIOTHYRONINE                      SYNTHROID

**HORMONAL AGENTS, SUPPRESSANT (ADRENAL) - HORMONAL AGENTS, SUPPRESSANT (ADRENAL)**

LYSODREN

**HORMONAL AGENTS, SUPPRESSANT (PARATHYROID) - HORMONAL AGENTS, SUPPRESSANT (PARATHYROID)**

SENSIPAR

**HORMONAL AGENTS, SUPPRESSANT (PITUITARY) - HORMONAL AGENTS, SUPPRESSANT (PITUITARY)**

CABERGOLINE	OCTREOTIDE	LEUPROLIDE	SOMATULINE
SOMAVERT	SYNAREL	TRELSTAR LA	ELIGARD
SANDOSTATIN			

**HORMONAL AGENTS, SUPPRESSANT (SEX HORMONES/MODIFIERS) - ANTIANDROGENS**

BICALUTAMIDE                      FLUTAMIDE                      NILANDRON                      XTANDI

ZYTIGA

**HORMONAL AGENTS, SUPPRESSANT (THYROID) - ANTITHYROID AGENTS**

METHIMAZOLE                      PROPYLTHIOURACIL

This document and the data and/or information contained in this document ("Information") are owned by EHIM. It contains legally privileged, confidential and proprietary information and/or intellectual property of EHIM that is protected from disclosure through agreement(s) and/or laws that require the recipient to keep the information confidential. The Information may not be reproduced, disclosed, used and/or relied upon, in whole, or in part, without the prior written consent of EHIM. This information is also intended solely for the recipient and/or others authorized by EHIM to receive it. If you are not the intended recipient, please notify EHIM and immediately delete, shred and/or otherwise destroy the Information. Any unauthorized reproduction, disclosure, access, use and/or action in reliance on the Information is strictly prohibited and may entitle EHIM to legal and/or equitable remedies and damages.